N(4)-Hydroxycytidine CAS 3258-02-4 EIDD-1931 NHC High Quality
Supply with High Purity and Stable Quality
Chemical Name: N(4)-Hydroxycytidine; EIDD-1931 (NHC)
CAS: 3258-02-4
An active metabolite of Molnupiravir, a promising COVID-19 inhibitor
| Chemical Name | N(4)-Hydroxycytidine |
| Synonyms | EIDD-1931 (NHC); β-D-N4-Hydroxycytidine |
| CAS Number | 3258-02-4 |
| CAT Number | RF-PI309 |
| Stock Status | In Stock, Production Scale Up to Kilograms |
| Molecular Formula | C9H13N3O6 |
| Molecular Weight | 259.22 |
| Melting Point | 169.0~172.0℃ |
| Solubility | Soluble to 100 mM in DMSO and to 50 mM in Water |
| Density | 1.93±0.1 g/cm3 |
| Brand | Ruifu Chemical |
| Item | Specifications |
| Appearance | White to Off-White Powder |
| NMR | Consistent with Structure |
| Purity / Analysis Method | >98% (HPLC) |
| Loss on Drying | ≤1.0% |
| Single Impurity | ≤0.50% |
| Heavy Metals | ≤20ppm |
| Test Standard | Enterprise Standard |
| Usage | An active metabolite of Molnupiravir (EIDD-2801), a COVID-19 inhibitor |
Package: Bottle, Aluminum foil bag, Cardboard drum, 25kg/Drum, or according to customer's requirement.
Storage Condition: Store in sealed containers at cool and dry place; Protect from light, moisture and pest infestation.
N(4)-Hydroxycytidine (EIDD-1931 , β-d-N4-hydroxycytidine, NHC, CAS 3258-02-4) is an active metabolite of EIDD-2801, a promising COVID-19 inhibitor. EIDD-1931 (NHC) has broad spectrum antiviral activity against multiple coronaviruses, including SARS-CoV-2, MERS-CoV, SARS-CoV, and related zoonotic group 2b or 2c Bat-CoVs with average IC50 of 0.15 μM, as well as increased potency against a coronavirus bearing resistance mutations to the nucleoside analog inhibitor remdesivir. In mice infected with SARS-CoV or MERS-CoV, both prophylactic and therapeutic administration of Molnupiravir (EIDD-2801), an orally bioavailable NHC-prodrug (β-D-N4-hydroxycytidine-5'-isopropyl ester), improved pulmonary function, and reduced virus titer and body weight loss. Decreased MERS-CoV yields in vitro and in vivo were associated with increased transition mutation frequency in viral but not host cell RNA, supporting a mechanism of lethal mutagenesis in CoV. The potency of NHC/EIDD-2801 against multiple coronaviruses and oral bioavailability highlight its potential utility as an effective antiviral against SARS-CoV-2 and other future zoonotic coronaviruses.
